Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.
Journal: The lancet. Gastroenterology & hepatology
Published: June 16, 2021
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
Journal: The lancet. Gastroenterology & hepatology
Published: June 16, 2021
Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.
Journal: The lancet. Gastroenterology & hepatology
Published: June 16, 2021
Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials.
Journal: The lancet. Gastroenterology & hepatology
Published: June 16, 2021
An Open-Label Tolerability and Actual-Use Human Factors Study of Etrolizumab Autoinjector in Healthy Volunteers.
Journal: Advances in therapy
Published: December 23, 2020
Listening to the Patient: Improving the Design and Conduct of Clinical Trials in Inflammatory Bowel Diseases.
Journal: Crohn's & colitis 360
Published: March 20, 2020
The role of integrins in the pathogenesis of inflammatory bowel disease: Approved and investigational anti-integrin therapies.
Journal: Medicinal research reviews
Published: January 23, 2019
Safety of rituximab in combination with other biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: an open-label study.
Journal: The Journal of rheumatology
Published: April 03, 2013
Showing 1-11 of 11
Last Updated: 09/26/2026